$2.40
0.21% yesterday
Nasdaq, Dec 05, 10:00 pm CET
ISIN
US2683111072
Symbol
EDAP

EDAP TMS SA Sponsored ADR Stock price

$2.40
+0.32 15.38% 1M
+0.59 32.60% 6M
+0.19 8.60% YTD
+0.08 3.45% 1Y
-8.61 78.20% 3Y
-1.85 43.53% 5Y
-2.05 46.07% 10Y
-1.58 39.70% 20Y
Nasdaq, Closing price Fri, Dec 05 2025
+0.01 0.21%

Key metrics

Basic
Market capitalization
$89.6m
Enterprise Value
$84.3m
Net debt
positive
Cash
$12.3m
Shares outstanding
37.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.2 | 1.3
EV/Sales
1.1 | 1.2
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
47.5%
Return on Equity
-46.5%
ROCE
-68.0%
ROIC
-84.6%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$74.3m | $70.2m
EBITDA
- | $-27.6m
EBIT
$-23.8m | $-30.1m
Net Income
$-22.9m | $-30.8m
Free Cash Flow
$-19.0m
Growth (TTM | estimate)
Revenue
0.1% | -6.0%
EBITDA
- | -31.7%
EBIT
-0.7% | -25.8%
Net Income
11.3% | -39.1%
Free Cash Flow
53.9%
Margin (TTM | estimate)
Gross
43.2%
EBITDA
- | -39.3%
EBIT
-32.0%
Net
-30.8% | -43.9%
Free Cash Flow
-25.6%
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
0.1%
Employees
310
Rev per Employee
$240.0k
Show more

Is EDAP TMS SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

EDAP TMS SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:

Buy
67%
Hold
33%

Financial data from EDAP TMS SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
74 74
0% 0%
100%
- Direct Costs 42 42
3% 3%
57%
32 32
101% 101%
43%
- Selling and Administrative Expenses 46 46
3% 3%
62%
- Research and Development Expense 10 10
120% 120%
14%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -24 -24
1% 1%
-32%
Net Profit -23 -23
11% 11%
-31%

In millions USD.

Don't miss a Thing! We will send you all news about EDAP TMS SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EDAP TMS SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
16 days ago
EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU  AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for new ultrasound imaging and workflow enhancements to the Focal One High Intensity Focused Ultrasound ...
Neutral
GlobeNewsWire
18 days ago
EDAP to Present at Piper Sandler 37th Annual Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Tuesday, December 2 nd , 2025 AUSTIN, Texas, November 18, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Chief Executive Officer Ryan Rhodes is scheduled to present and, together with Chief Financia...
Neutral
Seeking Alpha
30 days ago
EDAP TMS S.A. ( EDAP ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Conference Call Participants John Fraunces - Lifesci Advisors, LLC Charles Wallace - H.C.
More EDAP TMS SA Sponsored ADR News

Company Profile

EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Head office France
CEO Ryan Rhodes
Employees 310
Founded 1979
Website focalone.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today